VESUGEN 20MG

Vesugen 20mg is a synthetic tripeptide bioregulator with the amino acid sequence Lys-Glu-Asp (KED), developed by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology. Derived by identifying the shortest active fragment of Ventfort — the natural polypeptide complex extracted from young animal vascular tissue — Vesugen is the dedicated vascular member of the Khavinson bioregulator family, studied for its tissue-specific regulatory activity in vascular endothelial cells and smooth muscle of the arterial wall.

Research into Vesugen centers on its proposed epigenetic mechanism of direct DNA binding in endothelial cell nuclei, modulating gene expression programs governing vascular cell proliferation, intercellular communication via connexin proteins, and endothelial integrity. Preclinical studies have examined its effects on Ki-67 gene expression controlling cell division, endothelin-1 modulation in atherosclerotic and restenotic vascular models, SIRT1 upregulation linked to DNA repair and vascular aging, and endothelial homeostasis under conditions of chronic vascular stress.

Within the Khavinson cardiovascular research system, Vesugen is frequently studied alongside Cardiogen — Vesugen targeting the vascular endothelium while Cardiogen targets cardiomyocytes — offering complementary tools for comprehensive cardiovascular aging research panels.

Beyond Health Lab supplies Vesugen 20mg as a research-grade lyophilized compound, HPLC-verified for 99% purity, shipped within 24 hours from Mexico.

For research use only. Not intended for human or animal consumption.

FAQ:

What is Vesugen and what vascular cells does it target?
Vesugen (Lys-Glu-Asp / KED) is a Khavinson tripeptide bioregulator derived from the active fragment of Ventfort, a natural vascular tissue extract. It is studied for its tissue-specific regulatory activity in vascular endothelial cells — the cells lining the interior surface of blood vessels — and smooth muscle cells of the arterial wall. Its proposed mechanism involves direct DNA binding in endothelial cell nuclei to modulate gene expression programs governing vascular integrity, cell proliferation, and intercellular communication, distinguishing it from receptor-based vasodilators or antihypertensive compounds.

What specific molecular targets has Vesugen been studied for in preclinical research?
Published research has examined Vesugen’s effects on Ki-67 gene expression governing endothelial cell division, endothelin-1 modulation in atherosclerotic and restenotic vascular models, connexin protein expression maintaining endothelial gap junction integrity, and SIRT1 upregulation — a longevity-associated protein linked to DNA repair and vascular aging resistance. These molecular targets place Vesugen among the most well-characterized vascular bioregulators in the Khavinson peptide family.

How does Vesugen relate to Cardiogen in cardiovascular aging research?
Within the Khavinson cardiovascular research system, Vesugen and Cardiogen are complementary tools targeting distinct tissue compartments. Vesugen (KED) targets the vascular endothelium and arterial wall — relevant to atherosclerosis, endothelial dysfunction, and vascular aging research. Cardiogen (AEDR) targets cardiomyocytes and cardiac fibroblasts — relevant to myocardial aging and cardiac gene expression research. The two are frequently combined in comprehensive cardiovascular aging research protocols examining both myocardial and vascular components simultaneously.

How should Vesugen 20mg be stored?
Store lyophilized Vesugen at 2–8°C away from light and moisture. Once reconstituted with bacteriostatic water, keep refrigerated and use within 28 days for optimal stability and research-grade performance.